GHK-Cu for Skin Regeneration: Evidence, Off-Label Use, and Monitoring

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

What GHK-Cu is and how it is regulated

GHK-Cu is the copper(II) complex of GHK, a tripeptide found in human plasma, saliva and urine, with levels reported to decline with age; it is proposed that GHK works as a copper complex [7]. No FDA-approved drug contains GHK-Cu, and FDA treats it as a nominated bulk drug substance for compounding rather than an approved medicine [1][8]. It is a different compound from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [8].

Under the FD&C Act, cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, so copper peptide serums and creams reach the market as cosmetics [2]. Whether a product is a cosmetic or a drug turns on intended use: claims to treat disease, or to affect the body's structure or function, make it a drug, and FDA lists claims that a product will regenerate cells among the claims that establish a drug [2]. An injectable GHK-Cu product is not a cosmetic, and it is not FDA-approved [2].

What the human trials actually show

A 2006 randomized trial gave post-treatment skin care with or without GHK-Cu to patients whose circumoral skin had been resurfaced with a CO2 laser; 13 patients completed [4]. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, and no difference in wrinkle improvement or overall skin quality at 12 weeks. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [4]. That is 13 people, and the objective measures were negative.

The other randomized human trial found was not a cosmetic study. A 1992 trial randomized 86 evaluable patients with venous stasis ulcers to a 0.4% tripeptide copper complex cream, silver sulfadiazine 1%, or an inert vehicle [5]. The copper cream was no different from placebo on ulcer size, while silver sulfadiazine reduced it [5].

A 2026 systematic review searched the GHK-Cu literature from 2005 to 2026, identified 1,247 records and kept 64 for qualitative synthesis [9]. Its authors describe the human literature as thin and fragmented, note that most randomized trials are small and run on facial cosmetic creams, and state that microneedle delivery of GHK-Cu has not been evaluated in a single registered, adequately powered human randomized controlled trial [9].

Where the biological rationale comes from

The proposed mechanisms come from laboratory and animal work summarized by the researchers who proposed them: GHK is reported to stimulate collagen and proteoglycan production, modulate metalloproteinases, attract immune and endothelial cells to injury sites, and speed wound healing in dogs, rats, mice and pigs [7]. The same 2015 review states that GHK can up- and downregulate at least 4,000 human genes [7]. Its reports of cosmetic benefit, such as firmer skin and fewer fine lines, come mostly from laboratory and company-type data rather than randomized trials [7]. These are proposed mechanisms, not proven human effects.

Regulatory and compounding status

Non-injectable GHK-Cu, such as a topical cream, sits in category 1 of FDA's interim policy on bulk drug substances nominated for compounding, the group under evaluation for the bulks list. FDA says it generally does not intend to act against compounders for category 1 substances if the conditions in its guidance are met [1][10]. The listing has moved: it was removed on April 22, 2026 when the nominations were withdrawn, then added back (list updated May 14, 2026) after a nominator clarified that only the injectable route had been withdrawn [1][10]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the bulks list; no vote has taken place [1].

Injectable GHK-Cu is treated differently. It appears in FDA's table of bulk substances nominated but withdrawn, and FDA's stated concern is that 'compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3]. It is not in category 1 and not in any category on FDA's current list [1].

Two other lists matter here: GHK-Cu is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [11], and it is not on FDA's list for outsourcing facilities [12]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [13].

Safety: what is known and what is not

For injectable GHK-Cu the safety position is FDA's own: an immunogenicity risk from aggregation and peptide-related impurities, and limited human data to inform safety [3]. For topical use, the human data are the small trials described above [4][5].

Monitoring: what is established

No published monitoring schedule specific to GHK-Cu was identified in the human trials or in the FDA documents that address the substance [4][5][3]. The trials measured skin outcomes (ulcer size in one; redness, wrinkles and overall skin quality in the other) as study endpoints, not as a safety-monitoring schedule [4][5].

Frequently asked questions